These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 36714945

  • 1. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
    Uson Junior PLS, Bearss J, Babiker HM, Borad MJ.
    Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G, Mahipal A, John BV.
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M.
    Clin Cancer Res; 2023 Dec 01; 29(23):4853-4862. PubMed ID: 37773629
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M.
    Eur J Cancer; 2022 May 01; 166():165-175. PubMed ID: 35303508
    [Abstract] [Full Text] [Related]

  • 11. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ, Zhu AX.
    Oncotarget; 2016 Jul 19; 7(29):46750-46767. PubMed ID: 27102149
    [Abstract] [Full Text] [Related]

  • 12. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.
    PLoS Genet; 2014 Feb 19; 10(2):e1004135. PubMed ID: 24550739
    [Abstract] [Full Text] [Related]

  • 13. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS, Bearss J, Babiker HM, Borad M.
    Expert Opin Drug Saf; 2023 Feb 19; 22(8):637-641. PubMed ID: 37363820
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J, Lamarca A.
    J Hepatol; 2023 Mar 19; 78(3):652-657. PubMed ID: 36400328
    [Abstract] [Full Text] [Related]

  • 17. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
    Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, Mehrabi A, Brockschmidt A, Luedde T, Naumann P, Stenzinger A, Schirmacher P, Longerich T.
    Br J Cancer; 2022 Nov 19; 127(9):1701-1708. PubMed ID: 35986087
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N, Martinelli E, Melisi D, Pinto C, Rimassa L, Santini D, Scarpa A.
    ESMO Open; 2022 Jun 19; 7(3):100505. PubMed ID: 35696744
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.